Theralase Technologies Inc.: Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
TSXV:TLT)(
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (
UA ) has received site Institutional Review Board (
IRB ) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(
Study II ).
Theralase has central IRB approval to launch a number of US clinical sites, subject to local site IRB approval. UA is the second site to receive both central and local site IRB approval. There are 4 additional US clinical study sites that have received central IRB approval and are expected to receive loca